Trial Profile
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin: Part A: Dose Escalation of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer; Followed by Part B: an Expansion Phase of Olaparib in Combination With Carboplatin in the Neoadjuvant Treatment of HER-2 Negative Breast Cancer Patients With Germline BRCA1/2 Mutations
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Anthracyclines; Carboplatin; Cyclophosphamide
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 14 Feb 2017 Status changed from active, no longer recruiting to completed.
- 04 Jul 2016 Planned number of patients changed from 49 to 15.
- 04 Jul 2016 Planned End Date changed from 1 Nov 2018 to 1 Feb 2017.